1. (1) Schedule V consists of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this rule. Each drug or substance bears the federal controlled substance code number assigned to it by the Drug Enforcement Administration.

2. (2) Narcotic drugs containing non-narcotic active medicinal ingredients. Any compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below, which shall include one or more non-narcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal qualities other than those possessed by narcotic drugs alone:

   1. (a) Not more than 200 milligrams of codeine per 100 milliliters or per 100 grams.
   2. (b) Not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams.
   3. (c) Not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams.
   4. (d) Not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit.
   5. (e) Not more than 100 milligrams of opium per 100 milliliters or per 100 grams.
   6. (f) Not more than 0.5 milligrams of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit.

3. (3) Stimulants. Unless specifically exempted or excluded, or unless listed in another schedule, any material, compound, mixture or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of the isomers:

   1. (a) Pyrovalerone….…………………………………………………………………………… 1485

4. (4) Depressants. Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts:

   1. (a) Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide)……………. 2710
   2. (b) Cenobamate ([(1R)-1-(2-chlorophenyl)-2-(tetrazol-2- yl)ethyl]carbamate)…………. 2720
   3. (c) Ezogabine [N-[2-amino-4-(4-fluorobenzylamino)-phenyl]-carbamic acid ethyl ester] ….…………………………………………………………………………………………… 2779
   4. (d) Gabapentin [1-(aminomethyl)cyclohexaneacetic acid]
   5. (e) Ganaxolone (3-alpha-hydroxy-3-beta-methyl-5-alpha-pregnan-20-one)……………. 2401
   6. (f) Lacosamide [(R)-2-acetoamido-N-benzyl-3-methoxy-propionamide]……………….. 2746
   7. (g) Lasmiditan [2,4,6-trifluoro-N-(6-(1-methylpiperidine-4-carbonyl)pyridine-2- yl)benzamide]……………………………………………………………………………… 2790
   8. (h) Pregabalin [(S)-3-(aminomethyl)-5-methylhexonoic acid]…………………………….. 2782

Authority: T.C.A. §§ 4-4-103, 33-1-302, 33-1-303, 33-1-305, 33-1-309, and 39-17-403. Administrative History: Original rule filed April 29, 1981; effective June 18, 1981. Repeal and new rule filed May 25, 1984; effective June 24, 1984. Repeal and new rule filed September 6, 1985; effective October 10, 1985. Repeal and new rule filed December 17, 1986; effective January 31, 1987. Repeal and new rule filed January 7, 2011; effective April 7, 2011. Repeal and new rule filed December 20, 2013; effective March 20, 2014. Repeal and new rule filed February 24, 2015; effective May 25, 2015. Repeal and new rule filed March 4, 2016; effective June 2, 2016. Repeal and new rules filed March 21, 2017; effective June 19, 2017. Repeal and new rules filed July 5, 2018; effective October 3, 2018. Repeal and new rules filed October 1, 2019; effective December 30, 2019. Amendments filed October 1, 2020; effective December 30, 2020. Amendments filed September 24, 2021; effective December 23, 2021. Amendments filed March 1, 2024; effective May 30, 2024.